文献速递乳腺癌

绝经激素治疗对乳腺癌风险影响的更新

Update of the impact of menopausal hormone therapy on breast cancer risk.
PubMed 文献 · Eur J Cancer · 2025-03-11

这项全国性队列研究纳入1994-2019年芬兰357928名绝经激素治疗(MHT)使用者和351735名年龄匹配非使用者,随访至侵袭性乳腺癌发生。

要点

  • MHT使用者侵袭性乳腺癌发生率为6.6%,非使用者为4.9%(P<0.001)。
  • 雌二醇-孕激素治疗5-9年风险升高(OR 1.82;95%CI 1.76-1.88),高于单用雌激素(OR 1.61;95%CI 1.51-1.71)。
  • 多数MHT方案停药后5-10年乳腺癌风险仍升高。

核心结论

  • 尽管MHT处方可能已转向更安全的方案,但本研究数据主要采集于本世纪初,显示MHT使用者的乳腺癌风险升高幅度至少与既往研究相当。

研究设计与样本

  • 全国性队列研究,从医疗报销登记库识别1994-2019年MHT使用者357928名,从国家人口登记库识别年龄匹配非使用者351735名,通过芬兰癌症登记库随访侵袭性乳腺癌的发生。

主要发现

  • 单用雌激素治疗5-9年(OR 1.61;95%CI 1.51-1.71)或替勃龙使用≤10年(OR 1.30;95%CI 1.02-1.67)的风险升高幅度小于同疗程的雌二醇-孕激素治疗(OR 1.82;95%CI 1.76-1.88和OR 1.98;95%CI 1.91-2.06)。
  • 地屈孕酮-雌二醇-孕激素治疗5-9年的风险升高(OR 1.32;95%CI 1.12-1.55)小于其他雌二醇-孕激素方案(OR 1.76-2.16;95%CI 1.62-2.30)。
  • 多数MHT方案停药后5-10年乳腺癌风险仍升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We assessed menopausal hormone therapy (MHT) -related invasive breast cancer (BC) risks among more recent MHT users to compare this data with older national and international data. METHODS: We identified in this nationwide cohort study MHT users (n = 357 928) in 1994-2019 from the medical reimbursement register and age-matched non-users (n = 351 735) from the national population register and followed them for the occurrence of invasive BC with the aid of the Finnish Cancer Registry. The unadjusted BC risks were calculated as odds ratios (ORs) and 95 % confidence intervals (CIs). RESULTS: During a median of 18 years and 13 million person-years, 23 571 MHT users (6.6 %) and 17 192 non-users (4.9 %) were diagnosed with invasive BC (p < 0.001), and the median detection year was 2011. Ever use of estrogen-only therapy for 5-9 years (OR 1.61; 95 % CI 1.51-1.71) or tibolone for ≤ 10 years (1.30; 1.02-1.67) was accompanied by smaller risk elevations than use of estrogen-progestogen therapy (EPT) for the same duration (1.82; 1.76-1.88 and 1.98; 1.91-2.06). Dydrogesterone-EPT for 5-9 years was associated with a smaller risk increase (1.32; 1.12-1.55) than other EPT regimens (1.76-2.16; 1.62-2.30). The BC risks remained elevated 5-10 years after cessation of MHT with most of the regimens. CONCLUSIONS: Despite possible changes towards safer MHT prescribing, our data collected largely in early millennium show at least as large BC risk elevations in MHT users as seen in older studies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Siitonen H, Joensuu J, Savolainen-Peltonen H, et al. Update of the impact of menopausal hormone therapy on breast cancer risk. Eur J Cancer. 2025. PMID: 40107092. doi:10.1016/j.ejca.2025.115340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。